Project Grant R43MH143449
- The National Institute of Mental Health awarded New York University $0.00 on September 19, 2025, under the Mental Health Research Grants program (CFDA 93.242) for development of molecularly engineered nanocrystals capable of converting tissue-penetrating near-infrared light or X-ray to visible light for noninvasive optogenetic stimulation of nervous system structures. The project, titled "Tailoring Nanocrystals as a Versatile Platform for Noninvasive Neuroengineering," addresses...
- The National Institute of Mental Health awarded Quant, Inc. $1.835 million on September 25, 2025, under the Mental Health Research Grants program (CFDA 93.242) to develop ultra-high sensitivity, high spatial resolution single photon emission tomography using mechanical flux manipulation (MFM). The recipient will build on Phase 1 STTR work by advancing MFM technology, which employs high-resolution pixelated detectors and novel image reconstruction methodology leveraging detector flux information....
- The National Institute of Mental Health awarded Neurolux Inc. $1.248 million on September 24, 2025, under the Mental Health Research Grants program (CFDA 93.242) to develop and validate the Compliant Reversible Actuator and Detector Leveraging Electrophysiology for Organoids (ORGANOID-CRADLE). Neurolux will design and validate a multi-functional interface to measure and modulate neural organoid culture activity. The first-generation ORGANOID-CRADLE will integrate a multi-electrode array and...
- The National Institute of Mental Health awarded Scripps Research Institute $878,601 on April 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to support structural remodeling of neural circuits via multisynaptic boutons. The research uses three-dimensional electron microscopy at nanometer resolution to reconstruct neuronal connectomes, individual synapses, and glia in the mammalian brain. The work combines 3D-EM with chemogenetic techniques for labeling cellular ensembles...
- The National Institute of Mental Health awarded the University of Washington a cooperative agreement totaling $2,305,031 on March 9, 2026, to engineer red fluorescent calcium and neuromodulator sensors for multiplexed neuronal imaging. This work is funded under the Mental Health Research Grants program (CFDA 93.242). The project leverages the Opto-Mass sensor screening platform and machine learning models to accelerate fluorescent sensor development, addressing limitations in dynamic range,...
- The National Institute of Mental Health awarded $456,902 to 37Degrees, Inc. on August 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to develop INVITREON, a compact integrated platform for long-term neuronal culture incubation, recording, and closed-loop stimulation. The project runs through July 31, 2028, with performance in Chicago, Illinois. INVITREON addresses technical barriers in microelectrode array (MEA) culture systems used for disease modeling, neurotoxicity...
- This federal Project Grant award of $417,200.00, provided by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), aims to characterize and manipulate large-scale activity in the brain. The research will use simultaneous wide-field optical imaging (WOI) and functional magnetic resonance imaging (fMRI) in mice to determine whether the distribution of quasiperiodic patterns (QPPs) - recurring spatiotemporal patterns in intrinsic brain...
- The National Institute of Mental Health awarded Yale University $847,792 on July 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to develop integrated human thalamocortical assembloids that produce thalamocortical oscillations—brain rhythms representing inner states of the brain for vigilance and behavior. The project addresses the lack of tractable models for investigating human brain rhythm mechanisms, which are dysregulated in most neuropsychiatric and neurodegenerative...
- This Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) provides $434,610 to the Florida Institute of Technology Inc. (Florida TECH) for the development of light-triggered molecular tools to manipulate neuronal connections and study brain function. The principal investigator, Dr. Nasri Nesnas, will collaborate with neuroscientists, including Dr. Attila Losonczy from Columbia University, to design and utilize these...
- The National Institute of Mental Health (NIMH) awarded a $2,490,741 Project Grant under the Mental Health Research Grants program (CFDA 93.242) to President and Fellows of Harvard College (Harvard University) to develop the THERMAL-PLEX method. This fluidic-free, rapid sequential imaging technique enables multiplexed analysis of RNA and protein in brain tissues, providing critical insights into the spatial organization of molecular targets. The 3-year project aims to remove complex and slow...
The National Institute of Mental Health awarded Panluminate Inc. $454,646 on August 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to develop and validate a complete workflow for whole-brain pan-expansion microscopy (WBEXM) sample preparation and imaging. Panluminate will develop and optimize WBEXM protocols, including perfusion, embedding, clearing, and isotropic expansion procedures that preserve protein targets and tissue structure across entire mouse brains. The company will then validate reconstruction of neuronal processes across tissue sections to demonstrate that WBEXM enables faithful tracing of long-range neuronal projections, synapses, and local circuits while overcoming alignment errors inherent in slice-based approaches. WBEXM combines approximately 20-fold linear expansion of intact mouse brains with bulk pan-staining of proteins and lipids to enable molecularly annotated imaging of ultrastructure at sub-20 nanometer resolution. This optical, scalable, and cost-effective approach addresses current limitations of correlative light and electron microscopy for mapping nanoscale brain architecture and molecular features across entire mammalian brains, making it suitable for dense connectomics, circuit tracing, and investigation of neurodegenerative disease mechanisms. Panluminate Inc., a woman-owned small business headquartered in New Haven, Connecticut, is the recipient. The award period runs from August 1, 2026, through July 31, 2027, with work performed in Connecticut.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $454.6k | 7/31/26 |